Mason Michael 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 29, 2024
Insider Transaction Report
Form 4
Mason Michael
SVP, CFO & Treasurer
Transactions
- Sale
Common Stock
2024-02-27$1.32/sh−2,545$3,369→ 244,400 total - Award
Common Stock
2024-02-28+188,205→ 432,605 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.
- [F2]Represents the award of RSUs pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.